Skip to Content
Merck
CN
  • Optical coherence tomography angiography cyclic remodeling of CNV in patients affected by Best macular dystrophy.

Optical coherence tomography angiography cyclic remodeling of CNV in patients affected by Best macular dystrophy.

Ophthalmic genetics (2020-07-10)
Vittoria Murro, Dario Pasquale Mucciolo, Dario Giorgio, Andrea Sodi, Ilaria Passerini, Francesca Cipollini, Gianni Virgili, Fabrizio Giansanti
ABSTRACT

To evaluate the effect of photodynamic therapy and/or intravitreal injections on choroidal neovascularization in treatment-naïve patients affected by Best Macular Dystrophy using OCT-A. BMD patients with CNV treated using PDT and/or IV were included in the study. All patients underwent a complete ophthalmological examination, OCT and 3 × 3 mm OCT-A. The OCT-A images were analyzed using an open-source software (ImageJ) to assess the CNV membrane area (CNV-MA), the CNV vessel area (CNV-VA), and vessel density (VD) at the follow-ups (3 months after PDT and 1 month after IV). Five eyes of four patients with CNV were included. All eyes received PDT as first-line therapy; 4 eyes underwent more than 1 treatment session: three eyes received 1 IV, whereas one eye had one further PDT. After PDT, the CNV-MA, CNV-VA, and VD quantitative parameters were obtained for four out of five eyes: in three eyes of two patients CNV-MA, CNV-VA, and VD first decreased and then gradually increased during follow-up, whereas in one eye of one patient CNV-MA, CNV-VA, and VD slightly increased. After IV the CNV-MA, CNV-VA, and VD had significantly decreased at the 1-month follow-up in three eyes of three patients. OCT-A is an important tool for the diagnosis of both naïve and fibrotic CNV in BMD patients; it is a non-invasive method for the qualitative and quantitative analysis of neovascular lesions during follow-up. Our results have shown a cyclic remodeling of treated CNV in BMD patients using both PDT and IV.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
3-(2-Pyridyl)-5,6-diphenyl-1,2,4-triazine, ≥99%